Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07219511 · ClinicalTrials.gov registry record · Phase 1

A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

A Phase 1 study of Heart Failure With Preserved Ejection Fraction (HFPEF) and Heart, sponsored by Vasa Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
42
Enrollment target
17
Study locations

NCT07219511 is a Phase 1 study of Heart Failure With Preserved Ejection Fraction (HFPEF) and Heart that is actively recruiting participants, run by Vasa Therapeutics. The registered enrollment target is 42 participants, below the 215-participant average among 9 other Heart Failure With Preserved Ejection Fraction (HFPEF) trials with a reported enrollment target (80% lower). The trial reports 17 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07219511, a Phase 1 study of Heart Failure With Preserved Ejection Fraction (HFPEF) and Heart, is actively recruiting participants, sponsored by Vasa Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
42 participants
Enrollment target
17
Study locations

Study Summary

A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)

Conditions Studied

Heart Failure With Preserved Ejection Fraction (HFPEF) Heart

Interventions

  • OTHER Placebo
  • DRUG VS-041

Study Locations (17)

California

  • National Institute of Clinical Research - Huntington Beach
  • FOMAT - Santa Maria
  • Invivocure LLC - Van Nuys

Florida

  • New Generation of Medical Research - Hialeah
  • Jacksonville Center for Clinical Research - Jacksonville
  • Amavita Health - North Miami Beach

Illinois

  • Chicago Medical Research - Hazel Crest
  • Methodist Medical Center of Illinois - Peoria

Arkansas

  • Cardiology and Medicine Clinic - Little Rock

Louisiana

  • Louisiana Heart Center - Slidell

Missouri

  • Washington University - St Louis

New Jersey

  • Ash Research Clinic - Brick

New York

  • Erie County Medical Center - Buffalo

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2025-11-04
Est. Completion 2026-07
Phase Phase 1

Sponsor

Vasa Therapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07219511

The ClinicalTrials.gov registry entry for NCT07219511 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 215-participant average among 9 other Heart Failure With Preserved Ejection Fraction (HFPEF) trials with a reported enrollment target (80% lower). The listed sponsor is Vasa Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Heart Failure With Preserved Ejection Fraction (HFPEF) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07219511 reports 17 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT07219511 about?

NCT07219511 is a clinical study titled "A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)". A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)

What is the current status of trial NCT07219511?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2025-11-04. Estimated completion is 2026-07.

What conditions does trial NCT07219511 study?

This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction (HFPEF), Heart.

What interventions are being tested in trial NCT07219511?

The interventions under investigation include: Placebo (OTHER), VS-041 (DRUG).

Who is sponsoring clinical trial NCT07219511?

This trial is sponsored by Vasa Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07219511 being conducted?

This trial has 17 study locations across Arkansas, California, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure With Preserved Ejection Fraction (HFPEF)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure With Preserved Ejection Fraction (HFPEF)

All registered trials for this condition

Heart

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.